- Categories:About us
- Time of issue:2019-05-29 00:00:00
Zhang tong-cun , Chairman/General Manager
Dean of College of Life Science and Health，Wuhan University of Science and Technology；Professor；Doctoral Supervisor；
Special Professor of ChuTian Scholars in Hubei Province；Young and Middle-aged Experts with Outstanding Contributions in Hubei Province；“Hundred People Plan”of Hubei Province；“3551 Talent Plan”of Donghu High-tech Zone；
Special Professor of Tianjin；Director of Key Laboratory, Tianjin University of Science and Technology；Member of Tianjin Municipal Consultative Conference；
Engaged in the development of new biological drugs related to major human diseases, such as immunocytotherapy, gene regulation, etc.
Carl June, Chief Scientist
Carl June is the Director of the Center for Cellular Immunotherapies at the Perelman School of Medicine, and Director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania. He maintains a research laboratory that studies various mechanisms of lymphocyte activation that relate to immune tolerance and adoptive immunotherapy for cancer and chronic infection. In 2011, his research team published findings detailing a new therapy in which patients with refractory and relapsed chronic lymphocytic leukemia were treated with genetically engineered versions of their own T cells. The treatment has also now also been used with promising results to treat children with refractory acute lymphoblastic leukemia, and adults with refractory lymphoma. CTL019, the CAR T cell developed in the June laboratory was the first gene therapy to be approved by the US FDA in August 2017.
Gu chao-jiang, R&D Director
Ph.D，Wuhan University ；Professor of Wuhan University of Science and Technology；
Postdoctoral Research Scientist & Research Scientist of Columbia University Medical Center；Assistant Professor of Mount Sinai Medical center, NY；
“3551 Talent Plan”of Donghu High-tech Zone；
Engaged in HIV-related molecular virology and neurovirology；Design of the third generation lentivirus vector and CAR core molecule;
Applying for 25 patents and publishing 20 SCI papers
Zhou yong, R&D Director
Ph.D,Chinese Academy of Military Sciences；
Engaged in medical research on Stem Cells and Cellular Immunity for several years；
Applying for 6 patents and publishing more than 20 SCI papers；
Zhou Jing-jiao , R&D Director
Received a Ph. D. degree in Microbiology from the Sun Yat-sen University in 2007. She had completed the Postdoctoral training at the University of Pittsburgh Medical Centre, and was promoted to an Assistant Professor at the University of Pittsburgh in 2017. Dr. Zhou has been working on immunopathogenesis and immunotherapy for the solid tumors and infectious diseases over twenty years. Her research work has been published in many peer-reviewed Journals. She was also PI for many government funding and grants. Dr. In Wuhan Bio-raid, She works with R&D team together to develop multi-target combination therapy for the solid tumors and infectious diseases
Zhu Hai-chuan , R&D Director
PhD graduated from the Peking University.His major research is focus on identifying novel broad spectrum biomarkers for human cancers and exploring some combination therapy strategy for solid tumor targeting.
Zhang shang-kun Deputy General Manager and Production Supervisor
Ph.D, Engaged in cell culture technology research and cell product design of immune cells, primary cells, hybridoma cells and stem cells;
Applying for 10 patents and participation in 2 projects of the National Natural Science Foundation of China;
Zhang qing-xing Deputy General Manager and Quality Director
Proficiency in GMP Quality Management System of National Food and Drug Administration;
Scan the QR code to read on your phone
Wuhan Bio-Raid Biotechnology Co., Ltd.
Company address : 388 gaoxin 2nd road, east lake new technology development zone, wuhan city Floor 4, building 3, phase 3.1, wuhan optical valley international bio-pharmaceutical enterprise accelerator Floor 5-1
Phone number : 086-027-59318269